Customize sptl-2 Antibody

Description

Applications of SPTLC2 Antibodies in Research

SPTLC2 antibodies enable detection and functional analysis across experimental systems:

Application	Details	Citations
Western Blot (WB)	Detects ~63 kDa band in human/mouse tissues (e.g., liver, brain)
Immunohistochemistry	Localizes SPTLC2 in ER-rich regions of hepatocytes and neurons
Immunofluorescence	Visualizes ER-associated SPTLC2 in cultured cells
ELISA	Quantifies SPTLC2 expression in serum/plasma (sensitivity <1 ng/mL)

SPTLC2 in Disease Pathogenesis

Research using SPTLC2 antibodies has uncovered roles in metabolic and neurological disorders:

Neuropathy (HSAN-I)

Mutation impact: Over 20 HSAN-I-associated SPTLC2 mutations (e.g., C133W, V144D) reduce enzymatic activity by 40–70%, leading to neurotoxic 1-deoxysphinganine accumulation .
Therapeutic insight: Sphingolipid supplementation rescues T cell defects in HSAN-I patient-derived cells .

Atherosclerosis

Sptlc2 haploinsufficiency in macrophages:
- Reduces sphingomyelin by 55% in lipid rafts .
- Attenuates NF-κB activation (61% of wild-type levels) and decreases atherosclerosis in Ldlr<sup>-/-</sup> mice .

Ciliogenesis

C. elegans sptl-2 mutants show 31% loss of ciliary ceramide and impaired intraflagellar transport .

Key Research Findings Using SPTLC2 Antibodies

Recent studies demonstrate SPTLC2's regulatory roles:

Model System	Finding	Reference
Hepatocytes (Mouse)	ER stress upregulates SPTLC2 via sXBP1, increasing ceramides by 2.3-fold
CD8+ T Cells (Human)	SPTLC2 deficiency increases mTORC1 activity by 80%, causing ER stress
C. elegans	sptl-2 mutants show 40% reduced ceramide levels and ciliary defects

Product Specs

Buffer

Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4

Form

Liquid

Lead Time

Made-to-order (14-16 weeks)

Synonyms

sptl-2 antibody; F43H9.2 antibody; Serine palmitoyltransferase 2 antibody; EC 2.3.1.50 antibody; Long chain base biosynthesis protein 2 antibody; LCB 2 antibody; Serine-palmitoyl-CoA transferase 2 antibody; SPT 2 antibody; SPT2 antibody

Target Names

sptl-2

Uniprot No.

Q20375

Target Background

Function

This antibody targets SPTL-2, a component of the serine palmitoyltransferase (SPT) enzyme complex. SPT catalyzes the initial and rate-limiting step in sphingolipid biosynthesis, specifically the condensation of an acyl-CoA species and L-serine. The catalytic core of SPT is formed by a heterodimer of SPTL-1 and either SPTL-2 or SPTL-3. SPTL-2 is essential for the establishment of apicobasal polarity and the proper development of the gut lumen.

Database Links

KEGG: cel:CELE_F43H9.2

STRING: 6239.F43H9.2b

UniGene: Cel.3598

Protein Families

Class-II pyridoxal-phosphate-dependent aminotransferase family

Q&A

Here’s a structured collection of FAQs tailored for academic researchers working with sptl-2 Antibody, incorporating methodological guidance and evidence-based insights:

Advanced Research Questions

How do I resolve contradictions in sptl-2 Antibody’s binding affinity data across studies?

Potential causes:

Factor	Impact	Resolution
Glycosylation state of target	Alters epitope accessibility	Use enzymatic deglycosylation (PNGase F)
Conformational flexibility	Affects SPR measurements	Employ cryo-EM for structural validation

Validation: Cross-reference with alanine-scanning mutagenesis to identify critical binding residues .

What mechanisms underlie sptl-2 Antibody resistance in hyperproliferative disorders?

Observed mechanisms:
- Upregulation of EFNA receptors (competing with antibody binding) .
- Activation of compensatory signaling pathways (e.g., MAPK/ERK) .
Experimental design:
- Combine sptl-2 with small-molecule inhibitors (e.g., MEK inhibitors) in NTX models .
- Use single-cell RNA sequencing to identify resistant subpopulations .

How can sptl-2 Antibody be engineered to enhance neutralization breadth?

Strategies:
- Structure-guided design: Modify CDR regions to target conserved epitopes (e.g., β-hairpin motifs in N-terminal domains) .
- Glycan shielding evasion: Introduce mutations to bypass steric hindrance from N17/N74 glycans .
Validation: Test engineered variants in pseudovirus neutralization assays .

Data Integration and Reporting

What statistical methods are robust for analyzing sptl-2 Antibody efficacy data?

Recommended tests:
- Mixed-effects models for longitudinal tumor growth data .
- Benjamini-Hochberg correction for transcriptomic analyses to control false discovery rates .

How do I address batch variability in sptl-2 Antibody production?

Quality control pipeline:
- HDX-MS to confirm structural integrity.
- BLI (biolayer interferometry) for batch-to-batch affinity comparisons.
- In vivo validation in a standardized NTX model .

Key Technical Challenges

Why does sptl-2 Antibody show differential activity in immune vs. non-immune cell types?

Hypothesis: Fcγ receptor-mediated trogocytosis in immune cells .
Experimental approach:
- Use Fc-silent variants (L234A/L235A mutations) to isolate antigen-specific effects .

Quick Inquiry

Personal Email Detected

Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *

Name*

Email*

Phone

Country

Source

Quantity&Size*

Product Name

Message

sptl-2 Antibody